PharmEasy Investor Marks Down Its Valuation To $456 Mn

PharmEasy, the Indian online pharmacy platform, has seen its valuation reduced to $456 million, marking a significant decline from its earlier peak valuation. The markdown comes amid a challenging fundraising environment and concerns over the company’s financial performance. PharmEasy, which had once been one of the highest-valued healthtech startups in India, is facing pressure to demonstrate profitability and long-term sustainability. The markdown reflects the tightening market conditions, particularly in the Indian startup ecosystem, where investors have become more cautious amid macroeconomic uncertainties. The company is now focusing on operational efficiency to navigate these challenges.